CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNSP Stock Price Chart Interactive Chart >
CNSP Price/Volume Stats
| Current price | $2.01 | 52-week high | $4.46 |
| Prev. close | $1.98 | 52-week low | $1.59 |
| Day low | $1.96 | Volume | 72,800 |
| Day high | $2.01 | Avg. volume | 1,027,339 |
| 50-day MA | $1.99 | Dividend yield | N/A |
| 200-day MA | $2.18 | Market Cap | 50.97M |
CNS PHARMACEUTICALS, INC. (CNSP) Company Bio
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
Latest CNSP News From Around the Web
Below are the latest news stories about CNS Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNSP as an investment opportunity.
Lyophilization Services for Biopharmaceuticals Market - CNS Pharmaceuticals, Jubilant HollisterStier LLC, Lyophilization Technology, Inc. (LTI), GILYOS GmbH, Lyophilization Services of New England, Inc., Piramal Pharma Solutions Inc.Lyophilization Services for Biopharmaceuticals Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Lyophilization Services for Biopharmaceuticals industry overview and then goes into each and every detail. Lyophilization Services for Biopharmaceuticals Market Report |
GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug TrialBiopharmaceutical developer CNS Pharmaceuticals is working on ways to improve overall survivability for glioblastoma multiforme (GBM) brain cancer patients GBM is considered to be an incurable brain cancer that usually only leaves patients about 15 months to live once they are diagnosed, prompting research efforts to improve patients responses to therapeutic approaches A recent study Continue reading "GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial" The post GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial appeared first on NetworkNewsWire . |
CNS Pharmaceuticals Begins Enrollment, Screening Brain Cancer Study With BerubicinCNS Pharmaceuticals Inc (NASDAQ: CNSP ) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma Multiforme (GBM). The company intends to enroll approximately 210 subjects. The trial includes adult patients with recurrent glioblastoma multiforme after the Full story available on Benzinga.com |
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of BerubicinStudy to evaluate efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer Interim analysis of trial when 50% of planned subjects reach 6 months in study |
Did CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Insiders Buy Up More Shares?It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also... |
CNSP Price Returns
| 1-mo | 12.29% |
| 3-mo | -26.37% |
| 6-mo | -12.23% |
| 1-year | -18.62% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 12.92% |
| 2020 | -54.94% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...